TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20398339
Drug: Intramuscular artemether
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular artemether (3.6 mg/kg immediately followed by 1.8 mg/kg daily)
Study: 17512087
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream applied 3x/week for 4 weeks (course 1)
Study: 17512087
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream applied 3x/week for 4 weeks (course 1) and another course for remaining lesions
Study: 18242155
Drug: ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 8 mg i.v.
Study: 7653830
Drug: droperidol 2.5
Normalized name: droperidol 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: droperidol 2.5 mg i.v.
Study: 2720018
Drug: Treatment (Diazepam,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (Diazepam, Alprazolam)
Study: 789024
Drug: Th1165a (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Th1165a (5 mg)
Study: 789024
Drug: Th1165a (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Th1165a (10 mg)
Study: 789024
Drug: Th1165a (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Th1165a (15 mg)
Study: 789024
Drug: Th1165a (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Th1165a (20 mg)
Study: 789024
Drug: Metaproterenol sulfate
Normalized name: Metaproterenol Sulfate
DrugBank: Orciprenaline (DB00816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metaproterenol sulfate (20 mg)
Study: 30556110
Drug: Acalabrutinib 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acalabrutinib 15 mg
Study: 30556110
Drug: Acalabrutinib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acalabrutinib 400 mg
Study: 30556110
Drug: Acalabrutinib 100
Normalized name: acalabrutinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acalabrutinib 100 mg
Study: 25155034
Drug: Tadalafil 20
Normalized name: tadalafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 20 mg on demand (PRN)
Study: 23827533
Drug: Manualised Individual
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manualised Individual Cognitive Behaviour Treatment (M‐iCBT)
Study: 21272272
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy (CT) for up to 6 months
Study: 10767671
Drug: Active capsules
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active capsules containing 160 mg of bilberry extract (25-percent anthocyanosides) taken three times daily for 21 days
Study: 10767671
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules containing only inactive ingredients taken three times daily for 21 days
Study: 9496202
Drug: Felodipine 5
Normalized name: felodipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 5 mg orally, given daily for 5 days before operation
Study: 3332506
Drug: Mefloquine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine (250 mg) and sulfadoxine‐pyrimethamine once a week
Study: 3332506
Drug: Sulfadoxine‐pyrimethamine (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine‐pyrimethamine (two tablets) once a week
Study: 3332506
Drug: Sulfadoxine‐pyrimethamine (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine‐pyrimethamine (one tablet containing sulfadoxine 500 mg and pyrimethamine 25 mg) twice a week
Study: 27703984
Drug: Advantix (permethrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advantix (permethrin and imidacloprid combination)
Study: 23870287
Drug: C.E.R.A. (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: C.E.R.A. (any administration interval)
Study: 23870287
Drug: Shortening administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Shortening administration interval (Q2W)
Study: 19276275
Drug: Molecularly targeted
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecularly targeted agents
Study: 11413177
Drug: Intravenous nitrates
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nitrates
Study: 11413177
Drug: Heparin, aspirin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin, aspirin, beta blockers, intravenous nitrates
Study: 11413177
Drug: Aspirin, aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, aspirin and heparin, coronary angiography
Study: 9163261
Drug: Ketoprofen 2
Normalized name: ketoprofen 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 2 mg/kg body weight i.v. 20 min before surgery
Study: 28881462
Drug: Ixekizumab (IXE)
DrugBank: Ixekizumab (DB11569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ixekizumab (IXE) 80 mg every 4 weeks (Q4W) or every 2 weeks (Q2W) after an initial 160 mg dose
Study: 28881462
Drug: Etanercept (ETN;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (ETN; 50 mg twice weekly)
Study: 26742907
Drug: Caffeine (65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (65 mg/cup espresso)
Study: 18482245
Drug: Propofol (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (3.5 mg.kg(‐1))
Study: 18482245
Drug: Propofol-Ketamine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol-Ketamine (2.5 mg.kg(‐1))
Study: 18482245
Drug: Propofol-Midazolam (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol-Midazolam (2.5 mg.kg(‐1))
Study: 12926840
Drug: Reflexology treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reflexology treatment (manual pressure on specific points in the feet and massage of the calf area)
Study: 4064532
Drug: Glucagon (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucagon (0.5 mg)
Study: 19378542
Drug: Metoclopramide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (20 mg)
Study: 26813451
Drug: Acetazolamide (ACET)
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide (ACET) 500 mg for two consecutive days
Study: 24716739
Drug: Pamidronate (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (90 mg per day for two days)
Study: 24716739
Drug: Pamidronate and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate and Placebo (both groups receive paracetamol)
Study: 15981758
Drug: RUTF supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: RUTF supplement
Study: 10368993
Drug: H2-receptor antagonist
Normalized name: H2-receptor antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2-receptor antagonist (H2-RA)
Study: 8813472
Drug: OCT radionuclide
Normalized name: Urimar Reformulated Oct 2013
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCT radionuclide therapy
Study: 6397178
Drug: Acarbose 300
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acarbose 300 mg/day for one month
Study: 6397178
Drug: Acarbose 100-400
Normalized name: acarbose 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose 100-400 mg/day for six months
Study: 31108379
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) combined with medication (n = 92)
Study: 31108379
Drug: Medication alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication alone (n = 75)
Study: 27510285
Drug: Low-dose UVA-1
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose UVA-1 phototherapy (30 J/cm2, 340-400 nm) - 30 sessions
Study: 22309796
Drug: Culturally-appropriate family-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally-appropriate family-based interventions developed through community collaboration; specific dosage and duration not mentioned.
Study: 17659972
Drug: Long-term treatment
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term treatment (continue steroids once daily for 12 months)
Study: 17659972
Drug: Short-term treatment
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term treatment (stop topical steroid treatment)
Study: 10102462
Drug: Fish diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish diet alone (3.6 g omega3 fatty acids/day)
Study: 10102462
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fish diet and moderate exercise
Study: 7597630
Drug: Titaniumtetrafluoride solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titaniumtetrafluoride solution
Study: 2185664
Drug: Protein refeeding
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein refeeding (80 g protein)
Study: 2185664
Drug: Carbohydrate refeeding
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate refeeding (80 g carbohydrate)
Study: 7093110
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg aspirin
Study: 26175097
Drug: NZBC extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: NZBC extract (300 mg day(‐1) CurraNZ™ containing 105 mg anthocyanin)
Study: 26175097
Drug: Placebo (PL,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PL, 300 mg microcrystalline cellulose M102)
Study: 24749261
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of naropine
Study: 7521832
Drug: Emergency treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emergency treatment of seizures and aggressive treatment of fever
Study: 7521832
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with an antiepileptic drug
Study: 2844494
Drug: Conversion enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conversion enzyme inhibitor
Study: 29462158
Drug: 600 mg/day
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/day DHA (from algal oil) for 16 weeks
Study: 16835968
Drug: DVd regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: DVd regimen with thalidomide (50 mg/d orally, increased to a maximum of 400 mg/d)
Study: 12639763
Drug: HRT (conjugated
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT (conjugated equine oestrogen 0.625 mg and medroxyprogesterone acetate 2.5 mg)
Study: 10928223
Drug: Daily 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily 2.5 mg risedronate
Study: 10928223
Drug: Cyclical 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclical 15 mg risedronate (2 out of 12 weeks)
Study: 1533165
Drug: High thoracic
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High thoracic epidural analgesia (TEA) with bupivacaine 0.375% plus sufentanil 1:200,000 (5 micrograms/mL) combined with general anesthesia (midazolam/N2O)
Study: 29609070
Drug: Reverse hybrid
Normalized name: OraVerse
DrugBank: Phentolamine (DB00692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reverse hybrid therapy (proton pump inhibitor plus amoxicillin for 14 days, and clarithromycin plus metronidazole for the initial 7 days)
Study: 29609070
Drug: Bismuth quadruple
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth quadruple therapy (pantoprazole, bismuth, tetracycline, and metronidazole for 14 days)
Study: 26632893
Drug: Reverse hybrid
Normalized name: OraVerse
DrugBank: Phentolamine (DB00692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reverse hybrid therapy
Study: 31523279
Drug: Bismuth quadruple
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth quadruple therapy
Study: 24055515
Drug: Site-reported duplex
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Site-reported duplex ultrasound (DU) scans prior to treatment
Study: 24055515
Drug: UCL review
Approvals — FDA: no, EMA: no, PMDA: no
Description: UCL review of prior-to-treatment scans
Study: 7589048
Drug: Piroxicam 10
Normalized name: piroxicam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 10 mg
Study: 16962674
Drug: AV sequential
Normalized name: AVS-100
DrugBank: AVS-100 (DB18068)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AV sequential pacing at septum (DDDspt)
Study: 16962674
Drug: AV sequential
Normalized name: AVS-100
DrugBank: AVS-100 (DB18068)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AV sequential pacing at RV apex (DDDapx)
Study: 12394665
Drug: Early active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early active treatment program
Study: 8852495
Drug: Doxazosin (Cardura)
Normalized name: doxazosin Oral Tablet [Cardura]
DrugBank: Doxazosin (DB00590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxazosin (Cardura) 2-8 mg once daily or 8 mg b.i.d.
Study: 8852495
Drug: Captopril (Capoten)
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril (Capoten) 25-50 mg b.i.d.
Study: 8852495
Drug: Nifedipine (Procardia-XL)
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine (Procardia-XL) 30-60 mg once daily
Study: 31004340
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy (ESWT) combined with pharmacotherapy (alpha-blocker, anti-inflammatory agent, muscle relaxant, short course of antibiotic)
Study: 31004340
Drug: Sham-ESWT combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham-ESWT combined with pharmacotherapy
Study: 22633423
Drug: Fibrin sealant
Normalized name: FIBRIN SEALANT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin sealant (FS) containing 500 IU/mL thrombin and synthetic aprotinin
Study: 17678487
Drug: Antiplatelet agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet agents (i.e., clopidogrel)
Study: 17678487
Drug: Cholesterol-lowering agents
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol-lowering agents (i.e., statins)
Study: 2796617
Drug: 0.5% tetracaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% tetracaine 10 mg in hyperbaric solution
Study: 2796617
Drug: 0.5% tetracaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% tetracaine 10 mg in isobaric solution
Study: 356246
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium (Voltaren, 25 mg t.i.d.)
Study: 7044798
Drug: Indomethacin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (25 mg t.i.d.)
Study: 20820817
Drug: Tetracycline 500
Normalized name: oxytetracycline 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline 500 mg orally twice a day for 28 days
Study: 11509491
Drug: Transdermal clonidine
Normalized name: clonidine Transdermal System
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal clonidine patch (14 patients)
Study: 11509491
Drug: Transdermal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal placebo (12 patients)
Study: 8111799
Drug: Quinapril 10.0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril 10.0, 20.0, or 40.0 mg, or 20 mg plus 12.5 mg hydrochlorothiazide (HCTZ) given once daily
Study: 8111799
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg quinapril daily or 20 mg quinapril plus 12.5 mg HCTZ daily
Study: 31847158
Drug: Standard physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard physical therapy (control group)
Study: 2682025
Drug: Triiodothyronine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triiodothyronine administration at the end of operation and during the initial 24 hours after operation (study I)
Study: 2682025
Drug: Triiodothyronine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triiodothyronine administration (study II)
Study: 180405
Drug: High dosage
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dosage intermittent polychemotherapy, given as 3 infusions at intervals of a week for 3 years.
Study: 31944580
Drug: suvorexant 10
Normalized name: suvorexant 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: suvorexant 10 mg (could be increased to 20 mg based on clinical response)
Study: 27823800
Drug: Methylcobalamin 1000
Normalized name: METHYLCOBALAMIN 1000MCG CHEWABLE TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylcobalamin 1000 μg once daily for 27 months
Study: 27823800
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets once daily for 27 months
Study: 27823800
Drug: Methylcobalamin 1000
Normalized name: METHYLCOBALAMIN 1000MCG CHEWABLE TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylcobalamin 1000 μg
Study: 26056336
Drug: In-treatment SBP
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-treatment SBP ≤130 mm Hg
Study: 26056336
Drug: In-treatment SBP
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-treatment SBP 131 to 141 mm Hg
Study: 26056336
Drug: In-treatment SBP
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-treatment SBP ≥142 mm Hg
Study: 20619924
Drug: Annual low
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual low dose chest CT scans (CT group)
Study: 19572228
Drug: human follicle
Normalized name: Human follicle stimulating hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: human follicle stimulating hormone (hFSH)
Study: 15113814
Drug: Tolvaptan 30
Normalized name: tolvaptan 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan 30 mg/d
Study: 15113814
Drug: Tolvaptan 60
Normalized name: tolvaptan 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan 60 mg/d
Study: 15113814
Drug: Tolvaptan 90
Normalized name: tolvaptan 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan 90 mg/d
Study: 15113814
Drug: Tolvaptan (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan (all doses)
Study: 11353629
Drug: Intramuscular quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular quinine dihydrochloride (20 mg/kg of body weight)
Study: 23183442
Drug: Intramuscular quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular quinine
Study: 3500051
Drug: Methotrexate intravenous
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate intravenous bolus test doses (50 mg/m2) with folinic acid (15 mg every 6 h)
Study: 3500051
Drug: Methotrexate intravenous
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate intravenous bolus test doses (50 mg/m2) without folinic acid
Study: 3500051
Drug: 8 h
Normalized name: Tylenol 8 Hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 h infusion of methotrexate individualized to achieve a peak plasma concentration of 5 X 10(‐4) M
Study: 11496234
Drug: L-NMMA (inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (inhaled nitric oxide synthase inhibitor)
Study: 9284163
Drug: CVD 111
Normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVD 111 at high dose
Study: 9284163
Drug: CVD 111
Normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVD 111 at low dose
Study: 26765630
Drug: Mirror Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirror Training Group (MG)
Study: 22374408
Drug: TAK-875 (6·25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-875 (6·25, 25, 50, 100, or 200 mg)
Study: 18519992
Drug: Essential dental
Normalized name: Eucalyptus essential oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential dental treatment (EDT) at 13 to 21 weeks' gestation
Study: 18519992
Drug: Topical or
Normalized name: aloe vera topical oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical or local anesthetics during root planing
Study: 18519992
Drug: EDT and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDT and periodontal treatment
Study: 18519992
Drug: EDT or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDT or periodontal treatment alone
Study: 8647365
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin treatment
Study: 6369594
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with DTIC and cyclophosphamide (600 mg/m2 administered intravenously every 3 weeks for nine cycles)
Study: 6369594
Drug: Adjuvant immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant immunotherapy with Corynebacterium parvum (4 mg/m2 divided among the four extremities in 1- to 2-week cycles)
Study: 6369594
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with DTIC and cyclophosphamide
Study: 6369594
Drug: Adjuvant immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant immunotherapy with Corynebacterium parvum
Study: 31175052
Drug: Anthracycline chemotherapy
Normalized name: methacycline
DrugBank: Metacycline (DB00931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anthracycline chemotherapy (doxorubicin)
Study: 31175052
Drug: Non-anthracycline taxane
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-anthracycline taxane chemotherapy
Study: 29231163
Drug: Novel lyophilized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel lyophilized rapid-disintegrating tablet (bup-lyo)
Study: 29231163
Drug: Standard sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard sublingual buprenorphine tablet (bup-SL)
Study: 27099473
Drug: DLBS3233 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DLBS3233 at a dose of 50‐100 mg daily
Study: 12483466
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg/day for 6 months